$IOVA News

Iovance Biotherapeutics Announces Allowance To Proceed From FDA For Investigational New Drug Application For Phase 1/2 Basket Study Of IOV-5001

Chardan Capital Maintains Buy on Iovance Biotherapeutics, Lowers Price Target to $14

Iovance Biotherapeutics, Inc. (IOVA) Q1 2026 Earnings Call Transcript

Iovance Biotherapeutics (NASDAQ:IOVA) Reports Q1 Revenue Beat and Raised Guidance, Yet Stock Slips Pre-Market

Iovance Biotherapeutics Sees FY2026 Sales $350.000M-$370.000M vs $370.477M Est

Iovance Biotherapeutics Q1 EPS $(0.19) Misses $(0.16) Estimate, Sales $71.430M Miss $78.396M Estimate

Iovance Biotherapeutics to Report First Quarter 2026 Financial Results and Corporate Updates on Thursday, May 7, 2026

Is Viking Therapeutics, Inc. (VKTX) A Good Stock To Buy Now?

Chardan Maintains a Buy on Iovance Biotherapeutics (IOVA)

Is Iovance Biotherapeutics (IOVA) Pricing In Its Rebound After Strong Year To Date Gains?

Obsidian, Galera to advance cell therapy following reverse merger

Is This Biotech Stock the Best Chance to Make a Fortune in Healthcare?

Iovance Biotherapeutics Option Alert: Fri $4 Calls Sweep (3) Near The Bid: 2008 @ $0.401 Vs 3647 OI; Earnings 5/7 After Close [Est] Ref=$4.04

Iovance Biotherapeutics Option Alert: Fri $4 Calls Sweep (3) Near The Bid: 2008 @ $0.401 Vs 3647 OI; Earnings 5/7 After Close [Est] Ref=$4.04

Iovance Biotherapeutics: Competition Afoot, But New Indications Can Help

Iovance Biotherapeutics (IOVA) Down 2.1% Since Last Earnings Report: Can It Rebound?

Is It Time To Reassess Iovance Biotherapeutics (IOVA) After Its Recent Share Price Surge

Analyst Sentiment Remains Strong on Iovance Biotherapeutics (IOVA) Amid U.S. Rollout of Melanoma Drug, Amtagvi

Iovance Biotherapeutics (IOVA) Announces Positive Early Data for Lifileucel TIL Therapy in Advanced Sarcomas

Iovance Biotherapeutics, Inc. (IOVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript